Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP TMS S.A. to Release 2007 Second Quarter Results
EDAP TMS S.A. to Release 2007 Second Quarter Results LYON, France , Aug. 16 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and
View HTML
Toggle Summary EDAP TMS S.A. Updates 2006 Year End Revenue Estimates, Outlook
EDAP Leveraging Positions in Europe for HIFU; Finalizing US Market Strategy
View HTML
Toggle Summary EDAP TMS SA : EDAP Reports Q4 and Full Year 2018 Results
Reports record revenues for the fifth consecutive year Record fiscal year 2018 revenues of €39.2 million Q4 2018 HIFU net sales increased 79% year-over-year Profitable and cash flow positive during the fourth quarter of 2018 Completed first U.S. sale of Focal One at the end of 2018 Ended the year
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces CIGNA as First Major U.S. Private Health Insurer to Cover HIFU for Prostate Procedure
Insurer Takes its Cue from Updated NCCN Guidelines, Which Recognizes HIFU as Salvage Treatment for Prostate Cancer Lyon, France , Austin, TX -- March 21, 2018 - EDAP TMS SA (Nasdaq: EDAP) today announced that CIGNA became the first major U.S. private health insurance company to reimburse prostate
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces Expiration of Second and Final Tranche of Outstanding Warrants
Warrants for 1.5 Million Ordinary Shares in the Form of American Depository Shares Expired on November 29, 2018 Capital Structure Now Comprised Exclusively of Common Stock LYON, France , November 29, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound,
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces Expiration of Tranche of Outstanding Warrants
   Warrants for Approximately 3.3 Million Ordinary Shares in the Form of American Depository Shares Expired on October 14, 2018 LYON, France , October 15, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today that warrants for approximately
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces FDA Clearance for Focal One®
AUSTIN, TX , LYON, FRANCE -- JUNE 7, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, today announced that it has received 510(k) clearance from the US Food and Drug Administration ( FDA ) for its Focal One device for the ablation of prostate tissue. 
View HTML
Toggle Summary EDAP TMS SA : EDAP announces Installation of First Focal One HIFU device in South Korea
Successful HIFU Treatments Performed in Seoul National University Bundang Hospital LYON, France , September 20, 2018 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the installation of the first Focal One device in South Korea , at the renowned Seoul
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces Sales of Two Additional Focal One® Devices in Brazil
Hospital 9 de Julho and Hospital Moriah join growing roster of highly-regarded hospitals in Brazil offering Focal One LYON, France , January 14, 2019 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today that the Company has completed sales of
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces the Installation of a Third Focal One® HIFU Device in Brazil
HIFU Prostate Cancer Treatments Successfully Performed at Albert Einstein Hospital , Sao Paulo LYON, France , September 27, 2018 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the installation of the third Focal One device in Brazil at the renowned Albert
View HTML